Results 81 to 90 of about 22,609,350 (346)

Genome‐Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma

Advanced Science, EarlyView.
A genome‐wide microRNA CRISPR screen identifies miR‐18a as a master regulator of cross‐resistance in melanoma. Loss of miR‐18a activates the AJUBA–YAP/Hippo axis to confer BRAFi resistance and enhances THBS1–CD47 interaction to impair CD8+ T cell immunity. hnRNP A1 is identified as an upstream regulator of miR‐18a processing.
Zhao Wang, Haotian Liu, Xueqi Wang, Jianjin Teng, Zihan Zheng, Jingya Zhang, Wanyi Xiao, Qian Liang, Jiaxin Li, Xiaomeng Jia, Xin Feng, Hongzhang Cui, Menghan Luo, Tielong Yang, Liuxing Wu, Ke Zhao, Weilong Yang, Mulin Jun Li, Dandan Huang, Jilong Yang   +19 more
wiley   +1 more source

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Journal of Experimental Medicine, 1995
The importance of the B7/CD28/CTLA-4 molecules has been established in studies of antigen-presenting cell-derived B7 and its interaction with the T cell costimulatory molecule CD28.
M. Krummel, J. Allison
semanticscholar   +1 more source

CTLA-4 blockade induces tumor pyroptosis via CD8+ T cells in head and neck squamous cell carcinoma.

Molecular Therapy, 2023
Immune checkpoint blockade (ICB) treatment has demonstrated excellent medical effects in oncology, and it is one of the most sought-after immunotherapies for tumors.
Shuo Wang, Zhizhong Wu, Suding Zhu, S. Wan, Meng‐Jie Zhang, Boxin Zhang, Qi-Chao Yang, Yao Xiao, Hao Li, L. Mao, Zhi-Yong Wang, J. Gutkind, Zhi‐Jun Sun   +12 more
semanticscholar   +1 more source

Disruption of Treg Homeostasis in Rheumatoid Arthritis via Ferroptosis‐Mediated ETC Collapse and TXK‐STAT3/PLCγ1 Activation

Advanced Science, EarlyView.
In rheumatoid arthritis, synovial Tregs accumulate but are functionally impaired due to iron overload‐induced ferroptosis. This triggers mitochondrial dysfunction and TXK tyrosine kinase‐mediated signaling, leading to Treg destabilization and inflammation.
Jingrong Chen, Xiao Guan, Kexu Xiong, Xiaoyi Shi, Luyao Wu, Chuanxin Su, Jun Zhao, Rongzhen Liang, Huimin Wang, Junlong Dang, Ye Chen, Yiding Xiong, Chi Zhou, Futao Zhao, Zhenhang Zhu, Xiaoli Fan, Li Zhou, Nancy Olsen, Yutong Jiang, Song Guo Zheng   +19 more
wiley   +1 more source

Anti-PD-1 and anti-CTLA-4 treatment of Hep_Frag tumors.

, 2019
A, Treatment schedule: anti-PD-1 (10 mg/kg, i.p.) and anti-CTLA-4 (5 mg/kg, i.p.) therapy started at day 25 after fragment implantation and was applied in 3 doses at days 0, 3 and 7.
Veronika Schandl (6941093), Carola H. Ries (144688), Carina Hage (6941084), Fabian Kiessling (535383), Christian Heichinger (6941102), Sabine Hoves (6941087), Mailin Ashoff (6941090), Natascha Rieder (6941099), Marco Berrera (82653), Stefan Hört (6941096), Thomas Pöschinger (6941105)   +10 more
core   +1 more source

Anti-CTLA-4 Therapy for Malignant Mesothelioma [PDF]

Immunotherapy, 2017
Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1.
Guazzelli, A, Bakker, EY, Krstic-Demonacos, M, Lisanti, MP, Sotgia, F, Mutti, L   +5 more
openaire   +2 more sources

ROS Self‐Supply Nanoplatform Based on Fenton Catalyst for Chemodynamic and Immunotherapy: Reprogramming Cold Tumor Into Hot Tumor in Cancer Treatment

Advanced Science, EarlyView.
A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee, Jack Chun Hin Chen, Wai Wing Cheng, Kwan Yee Lau, Hiu Yee Kwan, Ngar‐Yun Ellen Poon, Hung‐Wing Li   +6 more
wiley   +1 more source

Supplementary Figures 1 - 4 from Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

, 2013
PDF file - 206K, Supplemental Figure S1. Equivalent binding of anti-CTLA-4 isotypes to cell surface CTLA-4. Supplemental Figure S2. Serum concentrations of anti-CTLA-4 isotypes in C57BL/6 mice. Supplemental Figure S3.
Mark J. Selby (3110964), Timothy Chen (3575390), Mohan Srinivasan (15111947), John J. Engelhardt (3110952), Karla A. Henning (15111944), Michael Quigley (3110970), Alan J. Korman (14907909)   +6 more
core   +1 more source

Additional file 2 of Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors

, 2021
Additional file 2: Table S1. CoGAPS 21 pattern matrix with pattern weights for each cell. Table S2. FDR adjusted gene set statistics for all 21 CoGAPS patterns. Table S3.
Emily F. Davis-Marcisak (9547348), Elizabeth M. Jaffee (7610147), Elana J. Fertig (9520792), Ludmila Danilova (3427982), Louis M. Weiner (11257778), Michael D. Kessler (5108738), Allison A. Fitzgerald (11257775), Neeha Zaidi (6244229)   +7 more
core   +1 more source

Tumor‐Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T‐Cell Infiltration and Limiting Myeloid Cell‐Mediated Immunosuppression

Advanced Science, EarlyView.
ARHGEF3 is broadly downregulated across human cancers and correlates with patient prognosis. Tumor‐intrinsic ARHGEF3 activates the RHOA–ROCK–PTEN cascade to inhibit AKT signaling, thereby promoting chemokine‐driven T‐cell infiltration and relieving lipid‐mediated myeloid immunosuppression.
Yue Li, Lan Wang, Zihao Zhang, Chunmei Qian, Ning Li, Wei Huang, Qian Ba, Xiaojian Liu, Mayu Sun   +8 more
wiley   +1 more source